Atlas Venture
56 Wareham StreetBoston, MA 2118
Firm Size
- Assets Under Management (AUM):$2.4 Billion
- Number of Funds:6
- Employees:
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Atlas Venture is a prominent venture capital firm based in Boston, Massachusetts. Founded in 1980, the firm focuses on early-stage investments in innovative life science and technology companies. With a deep expertise in biotechnology, therapeutics, and healthcare, Atlas Venture has established itself as a prominent investor in the Boston startup ecosystem. The firm has a proven track record of backing successful companies, having invested in more than 500 startups, including notable names like Novartis, Biogen, and Alnylam Pharmaceuticals. Atlas Venture takes a hands-on approach to investing, actively partnering with entrepreneurs to help them build and scale their businesses. Atlas Venture's investment strategy revolves around identifying transformative ideas and breakthrough technologies that have the potential to disrupt industries. By providing seed, early, and growth-stage funding, the firm supports startups from inception through various stages of development. Apart from capital, Atlas Venture provides mentorship, strategic guidance, and access to its extensive network to help entrepreneurs navigate challenges and maximize their chances of success. The firm's team comprises experienced professionals with diverse backgrounds in science, technology, and entrepreneurship, ensuring that portfolio companies receive comprehensive support. With a focus on Boston's thriving life sciences and technology sectors, Atlas Venture plays a crucial role in fostering innovation and supporting the growth of startups in the region. By connecting entrepreneurs with capital and expertise, the firm aims to catalyze breakthrough discoveries, drive economic development, and ultimately create value for its investors.Latest News
Powered by
May 21, 2024: Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline
Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, today announces the completion of a $120m Series B financing to fund the development of its pipeline of differentiated ADCs. The financing was led by TCGX with participation from other new investors BVF Partners, Lightspeed and Perceptive Advisors, alongside existing investors Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies.
Jan 23, 2024: Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies
Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the completion of a $75 million Series C financing. The financing was led by Mirae Asset Capital Life Science, with participation from other new investors, Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc., as well as all existing investors, including The Column Group, Atlas Venture, Droia Ventures, GV, EcoR1 Capital, AbbVie Ventures, The Mark Foundation for Cancer Research, Timefolio Capital (formerly known as NS Investment) and others. In conjunction with the financing, Naveen Krishnan , MD, MPhil, Managing Director of Mirae Asset Capital Life Science will join the Company's Board of Directors.
Jan 03, 2024: Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Oct 26, 2023: Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders
Triveni Bio Inc., a biotech company pioneering a genetics-informed precision medicine approach to develop functional antibodies for the treatment of I&I disorders, today announced a $92 million series A financing co-led by Atlas Venture and Cormorant Asset Management, with participation from OrbiMed, the private equity business of Viking Global Investors, Invus, Polaris Partners, Alexandria Venture Investments, and other investors.
Jun 28, 2023: K36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Trans
K36 Therapeutics ("K36"), a privately held clinical-stage biotech company developing KTX-1001, an investigational small molecule methyltransferase inhibitor of multiple myeloma SET (MMSET) domain, today announced a $70M Series B financing. The round was led by Nextech Invest, Ltd, a precision medicine focused investment firm, on behalf of one or more funds managed by it, with participation from Bristol Myers Squibb Company (NYSE:BMY), and other undisclosed investors. All existing investors including Atlas Venture, F-Prime Capital, and Eight Roads Ventures participated in the round.